• Facebook
  • Rss
  • Twitter
  • Youtube
  • Store
  • Donate
NCCS - National Coalition for Cancer Survivorship
  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Survivorship Champions
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Cancer Convos Podcast
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • Nominations
      • Honorees
      • Sponsors
      • Committees
    • From Shadows to Life: A Biography of the Cancer Survivorship Movement
    • Cancer Policy Roundtable
      • Spring 2021 Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us
  • Search
  • Menu Menu
  • 0Shopping Cart

Year-End MATCH (DEADLINE Dec 31): Donate & Make a Difference | Donate

NCCS Starburst 250px

Health Care Roundup: Trump Drug Pricing Plan; HHS Cuts ACA Navigator Funding; CAR-T Therapy Coverage Issues; Biosimilar News; and More

July 20, 2018/in Cancer News, Cancer Policy Blog Access to Care, Affordable Care Act, Drug Pricing, Health Care Coverage NCCS News /by actualize

In order to bring you the latest cancer-related health care policy and news, we at NCCS combined our ACA Updates and What Caught Our Eye (WCOE) content into a weekly email and blog post. We aim to make this a concise, one-stop summary of what you need to know as we continue working together to make cancer care better for everyone.

Your feedback is always welcome to make our content more useful to you. Please send comments to feedback@canceradvocacy.org.

Subscribe to our email list and receive these updates in your email box each week »


HEALTH CARE HIGHLIGHTS

Comment Period Closed for Trump Drug Pricing Plan

Comments for the Department of Health and Human Services’ (HHS) drug pricing proposal were due this week. The plan, introduced by the Trump administration, outlined proposals seeking to increase competition, reduce out-of-pocket costs and incentivize better negotiations for lower drug prices. NCCS joined with other organizations of the Cancer Leadership Council (CLC) to provide comments regarding the blueprint, called “American Patients First.”

Sent to HHS Secretary Alex Azar, the letter outlines the groups’ concerns and asks questions of HHS about the plan’s recommendations, with the hope of ensuring that patients’ physical and financial health are protected and considered a top priority.

We do not support changes in Part D formulary standards. Since the enactment of Medicare Part D and its implementation, cancer advocates have strongly supported the protected classes policy, which includes antineoplastics, as well as expansive formulary approaches.

Elimination of the protected classes policy and the implementation of restrictive formularies with aggressive formulary management tools may serve to limit timely access to cancer drugs.

– CLC Letter to HHS Secretary Azar on Drug Pricing Blueprint

The letter also outlined concerns for cancer patients regarding moving Medicare Part B drugs to Medicare Part D, posing the questions:

Will Part B coverage standards (for approved indications of cancer drugs and certain off-label uses) apply in the Part B to Part D shift? Will the payment system of Part B apply if drugs are shifted from B to D?

Hospitals Lose Suit Against 340B Cuts in Appeals Court

The U.S. Court of Appeals for the District of Columbia Circuit unanimously upheld a ruling in a case brought by the American Hospital Association and several other hospitals to prevent HHS from cutting $1.6 billion from the 340B drug discount program. The initial lawsuit was rejected last year after a federal judge ruled that the lawsuit was filed before the hospital plaintiffs experienced the cuts proposed by the Trump administration.

Hospitals that participate in the program receive higher reimbursement for 340B approved drugs through Medicare Part B. The cuts issued by HHS will reduce payments to 340B hospitals by 27 percent, a move that hospital groups say they will continue to fight. This ruling is the latest in the Trump administration’s push to reform the drug rebate system.

FDA Releases Guidelines on Speeding Development of Biosimilar Products

The Food and Drug Administration (FDA) announced earlier this week that it will take steps to speed up the development of biosimilars, generic versions of biologic drugs, by allowing for greater competition. This draft guidance is the latest in FDA Commissioner Scott Gottlieb’s goal to roll back regulations on the production of biosimilars in the United States, including the approval process of these drugs. Last month, the agency had withdrawn a draft guidance that outlined suggestions to companies producing biosimilars on how to evaluate analytical similarity between the two versions of drugs, citing the need for updated evaluation methods and greater flexibility for companies involved in developing biosimilars.

U.S. Death rates from liver cancer increase by over 40%

The Centers for Disease Control and Prevention (CDC) reported that liver cancer death rates shot up by 43 percent, placing liver cancer from the ninth leading cause of cancer death to the sixth. Men were more than twice as likely to die from liver cancer compared to women. “Obesity is a big risk factor that often goes overlooked,” said Dr. Sam G. Pappas, chief of the Division of Surgical Oncology at Rush University Medical Center.


CHART OF THE WEEK

Two charts from KFF highlight two important facts regarding the recently announced cuts to ACA navigator funding:

1) "The number of new marketplace participants was lower in 2018 compared to 2017."
2) Consumers seeking help "had limited understanding of the eligibility and enrollment process, or of health insurance, and lacked confidence to apply on their own."

Source: Kaiser Family Foundation, "Data Note: Further Reductions in Navigator Funding for Federal Marketplace States."


IMPORTANT READS

KFF on Funding Cuts for Federal Marketplace Navigators

Kaiser Family Foundation

Kaiser Family Foundation released a brief reviewing data CMS presented as justification for their decision to once again reduce funding for navigators, a marketplace-funded program created under the Obama administration. The navigators encourage those eligible for marketplace and Medicaid coverage to sign up through education, outreach, and enrollment guidance.

While CMS argued that knowledge on how to enroll in the marketplace is now wide-spread, KFF counters CMS claims by stating that millions of Americans lose their coverage each year and that understanding how enrollment works will continue to remain complicated, especially for low-income Americans and those without proper access to improved health literacy. The brief also highlights how data provided by CMS did not fully capture the extent of assistance navigators provided to beneficiaries. Read More »

Health Insurers Are Vacuuming Up Details About You—And It Could Raise Your Rates

Via National Public Radio (NPR)

This NPR article details how insurers and data brokers work together to collect personal details about millions of people in this country and how they utilize “lifestyle” data to set prices for health care plans. The information provided to insurers can range from your socioeconomic status to what you posted to social media last night. Health insurance companies can use these data to maximize their profits, but at the cost of health privacy for many. Diminishing privacy as well as the issue of poor inferences from the data insurers collects is an ongoing debate, and something that will not be resolved anytime soon. This information could become exponentially more harmful if efforts to repeal pre-existing condition protections are successful.
Read More »

Delays and Denials in Coverage for CAR-T Cancer Therapies

Via NPR

The process and costs towards coverage for CAR-T Cancer therapies is under scrutiny. Astronomical costs for therapy in addition to confusing and time-consuming approval processes have left many health care providers frustrated and patients overburdened, both financially and mentally. Private insurers are not the only ones who have received numerous criticisms in how they cover patients. Patients who rely on Medicaid and Medicare have also faced obstacles in ensuring adequate coverage. Some Medicaid programs do not provide coverage for the gene therapy. For Medicare, issues with reimbursement rates may further exacerbate problems with outpatient care for cancer patients. Read More »


Related Posts

https://canceradvocacy.org/blog/nccs-joins-clc-letter-hhs-drug-pricing-blueprint-american-patients-first/
https://canceradvocacy.org/blog/health-care-roundup-july-13-2018/

Tags: aca update, affordable care act, cancer care, Cancer Survivorship, drug pricing, FDA, immunotherapy, Medicaid, Medicare, What Caught Our Eye
Share this entry
  • Share on Facebook
  • Share on Twitter
https://canceradvocacy.org/wp-content/uploads/2017/01/NCCS-Starburst-250px.png 250 250 actualize https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png actualize2018-07-20 15:43:422018-07-20 15:43:42Health Care Roundup: Trump Drug Pricing Plan; HHS Cuts ACA Navigator Funding; CAR-T Therapy Coverage Issues; Biosimilar News; and More
You might also like
NCCS Starburst 250px What Caught Our Eye: House Passes ACA Repeal, Faces Senate Hurdles; Risky Prostate Cancer Treatment; Medical Debt; ‘Right to Try’; Rx Pricing
HHS Humphrey bldg 1200 NCCS and Other Cancer Groups Urge HHS to Keep Six Protected Classes in Medicare Part D Drug Plans
white house400by400 Share Your ACA Story
Tumor Could Provide Early Warning Shared Decision Making to Improve Care and Reduce Costs
affordable care act NCCS Position Statement on Actions to Undermine ACA
Elevating Survivorship Logo web FB TW 2020 NCCS Elevate Ambassadors Selected to Improve Survivorship Care in Local Communities
20years NCCS CEO Shelley Fuld Nasso Introduces the Fourth Principle of the Imperatives for Quality Cancer Care (VIDEO)
NCCS Starburst Thumbnail WCOE: When Doctors Don’t Talk to Doctors, “Below-the-Belt” Cancers, and the Psychological Effects of Chemo

Latest News

NCCS Founders at 1990 Assembly

The Birth of the Cancer Survivorship Movement and How It Transformed Cancer Care for Millions

March 25, 2021
Guest Post by Judith L. Pearson Best-Selling Author of From Shadows to Life: A Biography…
Read more
https://canceradvocacy.org/wp-content/uploads/2018/02/10-Founders-1990-NCCS-Assembly.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-25 10:36:202021-03-25 13:46:05The Birth of the Cancer Survivorship Movement and How It Transformed Cancer Care for Millions
HHS Humphrey bldg 1200

Biden Rescinds Trump Admin Proposal to Limit Medicare Part D Coverage of Drugs in “Six Protected Classes”

March 19, 2021
This week, the Biden administration rescinded a Trump administration-proposed plan…
Read more
https://canceradvocacy.org/wp-content/uploads/2017/10/HHS-Humphrey-bldg-1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-19 13:36:192021-03-23 14:46:18Biden Rescinds Trump Admin Proposal to Limit Medicare Part D Coverage of Drugs in “Six Protected Classes”
CDC Headquarters

NCCS Recommends That States Allocate COVID-19 Vaccines to Cancer Care Providers

March 1, 2021
The National Coalition for Cancer Survivorship (NCCS) and the Cancer Leadership Council…
Read more
https://canceradvocacy.org/wp-content/uploads/CDC_Headquarters_PHIL_pubdomain_1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-01 15:49:432021-03-04 17:45:07NCCS Recommends That States Allocate COVID-19 Vaccines to Cancer Care Providers

Take Action

Stovall Award

The Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care is a unique opportunity for patients and survivors to recognize pioneers who are transforming the cancer care system.

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Survivorship Champions
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Cancer Convos Podcast
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • Nominations
      • Honorees
      • Sponsors
      • Committees
    • From Shadows to Life: A Biography of the Cancer Survivorship Movement
    • Cancer Policy Roundtable
      • Spring 2021 Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2021 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

NCCS Awarded American Institutes for Research Grant to Develop New Outcome Measure:... NCCS News Cancer Policy Matters NCCS Starburst 250px Health Care Roundup: “Toxic Town” in WV Battles High Cancer Rates;...
Scroll to top

Harmar Brereton, MD

Founder
Northeast Regional Cancer Institute

 

“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”

—Karen M. Saunders
President, Northeast Regional Cancer Institute